Author

Jing Ni

Harvard UniversityORCID 0000-0002-4229-775XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 4 Assay:bulk RNA-seq· 3 Organism:mouse· 3 Research Focus:cell signaling & trafficking· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

Jean J. ZhaoiD· 4 shared Renlei JiiD· 2 shared Anwaruddin MohammadiD· 1 shared Apoorva BaluapuriiD· 1 shared Bose S. KochupurakkaliD· 1 shared Changli Qian· 1 shared Cherubin ManokaraniD· 1 shared Craig J. ThomasiD· 1 shared

Activity by Year

2017-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

Jean J. ZhaoORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer

Xin Cheng, Y Zhang, Changli Qian, Erica M. Holdridge, Guruprasad Ananda, Tao Jiang, Jing Ni, Shaozhen Xie, Hao Gu, Renlei Ji, Elena V. Ivanova, Marisa R. Nucci, Zhe Wang, Kaifu Chen, Bose S. Kochupurakkal, , Jean J. Zhao

This study identifies FGFR signaling as a driver of resistance and immune evasion in PIK3CA-driven serous-like endometrial cancer and shows that dual FGFR/PI3K inhibition improves tumor control.

Nature Communications · May 4, 2026Peer-reviewedCancer Biology

IRG1/itaconate/NRF2/GSH axis in tumor-associated macrophages drives therapy resistance and immune evasion in BRCA1-deficient breast cancer

Yabing Nan, Sophie O'Keefe, Xiadi He, Qingyu Luo, Xiaowei Wu, Jing Ni, Yutian Zou, Jerryd Marcus Meade, Yutong Li, Renlei Ji, Anwaruddin Mohammad, Pankaj Kumar, Qiwei Wang, Jean J. Zhao

This study identifies the IRG1/itaconate/NRF2/GSH axis in TAMs as a driver of PARPi resistance and immune evasion in BRCA1-deficient breast cancer, with pharmacological inhibition showing therapeutic potential.

bioRxiv · Oct 14, 2025 · PreprintCancer Biology

Dual Modes of Gene Regulation by CDK12

Yubao Wang, Apoorva Baluapuri, Cherubin Manokaran, Jing Ni, Tao Jiang, Roel C. Janssens, Jurgen A. F. Marteijn, Karen Adelman, Jean J. Zhao, Thomas M. Roberts

This study shows CDK12 inhibition both downregulates and upregulates gene expression, with implications for cancer therapy.

bioRxiv · Sep 22, 2025 · PreprintCancer Biology

Targeting neuronal activity-regulated neuroligin-3 dependency for high-grade glioma therapy

Humsa S. Venkatesh, Lydia T. Tam, Pamelyn J. Woo, James Lennon, Surya Nagaraja, Shawn M. Gillespie, Jing Ni, Damien Y. Duveau, Patrick J. Morris, Jean J. Zhao, Craig J. Thomas, Michelle Monje

This study shows that targeting Nlgn3 secretion via ADAM10 inhibitors can block high-grade glioma growth in mouse models.

Nature · Sep 1, 2017Peer-reviewedNeuroscience